IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

"Application of Bioanalytical Techniques in Monitoring Drug-Drug Interaction and Adverse Events"

[1]Aadil Khan, [2]Saufiyan N. Deshmukh, [3]Prof. Nikita V. Mahalle, [4]Prof. Suraj K. Yadav, [5]Dr. Harigopal S. Sawarkar,

[1,2]Student, [3]Associate Professor, [4]Associate Professor, [5]Principle,

[1,3]Department of Pharmacology, Dr. Rajendra Gode College Of Pharmacy,Amravati-444602,Maharashtra(India).

[2,4]Department of Pharmaceutics, Dr. Rajendra Gode College Of Pharmacy,Amravati-444602,Maharashtra(India).

[5]Department of Pharmaceutical Chemistry, Dr. Rajendra Gode College Of Pharmacy,Amravati-444602,Maharashtra(India).

Abstract

Drug-drug interactions (DDIs) and adverse drug reactions (ADRs) are major challenges in modern pharmacotherapy, often leading to therapeutic failure, increased healthcare burden, or severe toxicity. Bioanalytical techniques have become indispensable tools in identifying, monitoring, and managing DDIs and ADRs across preclinical, clinical, and post-marketing phases. This review highlights the role of bioanalytical methodologies such as chromatography, mass spectrometry, spectroscopy, immunoassays, etc in evaluating drug interactions and detecting adverse events. Additionally, the review explores regulatory perspectives, clinical applications, and future trends in integrating bioanalytical tools into pharmacovigilance and personalized medicine

***Keywords*:** Bioanalysis , Pharamacovigilance , Spectroscopy ,Chromatography , Adverse Events.

INTRODUCTION

Although drug safety is an essential part of pharmacotherapy adverse drug reactions (ADRs) and drug–drug interactions (DDIs) continue to be major problems for healthcare systems around the world. When another co-administered agent alters a drugs pharmacokinetics (absorption distribution metabolism and excretion) or pharmacodynamics it can result in DDIs which can cause increased toxicity or therapeutic failure [1819]. The World Health Organization (WHO) defines adverse drug reactions (ADRs) as negative or unexpected reactions to medications at recommended dosages. ADRs are a major cause of hospitalizations and medical expenses globally. [19].With the growing prevalence of polypharmacy, particularly in elderly and chronically ill populations, the monitoring and early detection of DDIs and ADRs have become increasingly important in both clinical practice and drug development[18,19].

For the detection measurement and characterization of medications and their metabolites in biological matrices like plasma serum urine cerebrospinal fluid and tissues bioanalytical techniques offer strong instruments. Detailed pharmacokinetic and pharmacodynamic profiling is made possible by these techniques high sensitivity specificity and reproducibility [1822]. Drug monitoring has become dependent on methods like nuclear magnetic resonance (NMR) spectroscopy capillary electrophoresis gas chromatography (GC) high-performance liquid chromatography (HPLC) liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS) and enzyme-linked immunosorbent assays (ELISAs) [5,6,13-15,18]. LC-MS/MS has become the gold standard among these because of its high analytical resolution and capacity to precisely quantify multiple drugs and metabolites at once [1,2,4,18,22].

The techniques are essential to be used in different phases of the drug lifecycle. Bioanalytical assays are used in drug development to perform pharmacokinetic, metabolic stability, and drug-enzyme interaction profiling, as well as predict potential DDIs before clinical exposure[18,21,22]. Bioanalytical monitoring in post-marketing surveillance Bioanalytical monitoring supports pharmacovigilance activities by containing mechanistic information on ADRs observed in real-life patient populations[18.19]. As

an example, inhibition/induction of cytochrome P450 enzymes by concurrently administered drugs can be directly measured with validated LC -MS / MS assays that connect clinical outcomes and molecular pathways[16,18] .

Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Central Drugs Standard Control Organization (CDSCO) in India underline the role of validated bioanalytical methods in therapeutic drug monitoring (TDM) and risk assessment[4,19,21,22]. The methods can be utilized in support of dose adjustment and contraindication changes as well as provide valuable evidence used in labeling changes and post-approval commitments. Moreover, there are recent developments in bioanalytical platforms which are being combined with pharmacogenomics and biomarker discovery, which make possible personalized medicine. It can be suggested that optimization of dosing regimens, minimization of ADRs, and prevention of detrimental DDIs in high-risk groups can be achieved by monitoring patient-specific drug levels, as well as genetic variability [16,22].

In summary bioanalytical methods are essential for tracking DDIs and ADRs because they help close the gap between clinical judgment and laboratory analysis. In a time of intricate treatment plans and precision medicine their function in guaranteeing medication safety effectiveness and patient welfare is becoming more and more important. Summing up current bioanalytical techniques emphasizing their use in DDI and ADR detection and talking about potential future developments in improving drug safety monitoring are the objectives of this review. [18,22].

Overview of Drug-Drug Interactions and Adverse Events

When the presence of one drug changes the pharmacological effect of another this is known as a drug-drug interaction. They fall into one of two categories: pharmacokinetic interactions which impact ADME processes or pharmacodynamic interactions which modify receptor-level reactions. ADRs however may arise from these kinds of interactions or from erratic individual reactions to a single medication. In order to avoid clinical complications like hepatotoxicity nephrotoxicity cardiotoxicity or therapeutic failure effective monitoring is crucial.

Bioanalytical Techniques in Monitoring DDIs and ADRs

Some techniques commonly used in bioanalytical studies include:

- Chromatographic Techniques.
- Spectroscopic Techniques.
- Immunoassays and Biosensors.

LIQUID CHROMATOGRAPHY-MASS SPECTROSCOPY(LC-MS)

Using liquid chromatography and mass spectrometry together is known as bioanalytical liquid chromatography-mass spectrometry. Drug substances drug products and biological samples are frequently analyzed quantitatively and qualitatively in labs using LC-MS. Bioavailability bioequivalence and pharmacokinetic data evaluation and interpretation have been greatly aided by LC-MS [1,2,3,6]. Biological samples are identified using LC-MS at every stage of a drugs method development in both quality control and research. [15-17].

Principle

1. Liquid Chromatography(LC)

Operates on the idea that compounds are separated according to how they interact with the mobile phase (solvent system) and stationary phase (column packing material). Different retention times are experienced by compounds that differ in their polarity solubility or affinity for the stationary phase [5,6].

2. Mass Spectrometry (MS)

Based on ionization of analytes into charged species and their separation according to mass-to-charge ratio (m/z). This provide a unique fingerprint for analytes[1,2,16].

3. Coupled LC-MS Principle

LC is used to first separate the drug molecules, metabolites, and impurities. These are then introduced into the MS where the compounds are ionized, and further analyzed on the basis of m/z. This hyphenated technique helps in qualitatively identifying (structural information) and quantitatively determining (concentration) the drugs in biological matrices [1,2,5,6,15,17].

Procedure

Taking some example (Ketoconazole & Midazolam) to explain LC-MS in better way

1. Sample Preparation
    - Plasma or serum samples are taken from patients or experimental models receiving both drugs.
2. Chromatographic Separation
    - Stationary Phase: C18 reverse-phase column.
    - Mobile Phase: Water (with 0.1% formic acid) and acetonitrile (organic solvent).

- This setup separates midazolam, ketoconazole, and their metabolites[15-17].

3. Mass Spectrometry Detection
   - Ionization Technique:Electrospray ionization (ESI).
   - Detection: Multiple Reaction Monitoring (MRM) mode is used to quantify midazolam and its hydroxylated metabolite[1,2,16].
4. Result
   - LC-MS/MS analysis showed significant decrease in midazolam metabolite (1'-hydroxymidazolam) with co-administration of ketoconazole and increase in parent drug concentration.
   - This confirms a drug –drug interaction due to CYP3A4inhibition[16,18].



Figure 1: Effect of Ketoconazole on Midazolam Plasma Levels.

Advantage of LC-MS

1. High Sensitivity & Specificity
   - Can detect drugs and metabolites at mg/mL levels, essential for pharmacokinetic studies.
   - Multiple Reaction Monitoring (MRM) mode increases selectivity[1,2,16].
2. Wide Range of Analytes
   - Suitable for both polar and non-volatile compounds (unlike GC-MS which needs derivatization).
   - Useful for complex drug combinations in DDI studies[5,6,12].
3. Simultaneous Multi-Analyte Detection
   - Can measure parent drugs + metabolites in a single run (e.g., Midazolam + Ketoconazole interaction studies).
4. Reduced Sample Preparations
   - Often requires only protein precipitation or SPE, making it faster than classical techniques.
5. Therapeutic Drug Monitoring (TDM)
   - LC-MS is widely used for monitoring plasma drug levels in patients to prevent toxicity and AEs[18,19].

Disadvantages of LC–MS

1. High Cost
   - Instruments, maintenance, and consumables are expensive[12,16].
2. Complex Operation
   - Requires trained personnel for method development, optimization, and troubleshooting[4,16].
3. Matrix Effects
   - Biological matrices (plasma, urine) can cause ion suppression/enhancement, leading to inaccuracies[1,16].
4. Time-Consuming Validation

- Regulatory requirements (FDA/EMA bioanalytical guidelines) demand rigorous method validation[4,17,18].

5. Limited Portability
   - Unlike rapid immunoassays, LC-MS is not bedside-applicable.

Future Prospects of LC–MS :

1. Integration with Pharmacogenomics
   - Coupling LC-MS drug quantification with genetic profiling (e.g., CYP450 polymorphisms) to predict personalized DDI risk[16,18].
2. High-Throughput & Automation
   - Development of ultra-fast LC–MS/MS platforms for large clinical trials and real-time monitoring[17,21].
3. Metabolomics & Biomarker Discovery
   - LC-MS used to identify novel toxic metabolites or biomarkers of drug-induced liver injury, nephrotoxicity, etc[12,16,22].
4. Miniaturized LC-MS Devices
   - Research into portable LC-MS systems may allow bedside or point-of-care DDI/AE monitoring in future[22].
5. Integration with AI & Big Data
   - Machine learning algorithms applied to LC-MS datasets will help predict complex DDIs and adverse outcomes[22].

Figure 2: LC-MS Instrument.

GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS)

One of the most effective bioanalytical methods is gas chromatography–mass spectrometry (GC–MS) which combines the structural identification capabilities of mass spectrometry with the separation capabilities of gas chromatography. Clinical toxicology pharmacovigilance and pharmaceutical research have all made extensive use of it because of its high sensitivity repeatability and ability to analyze drugs and their metabolites both qualitatively and quantitatively [9-13].

In the context of drug–drug interactions (DDIs), GC–MS plays a pivotal role in identifying alterations in metabolic pathways when two or more drugs are co-administered. Many clinically important DDIs result from enzyme inhibition or induction (e.g., cytochrome P450 system), leading to accumulation of toxic metabolites or Reduced therapeutic efficacy[9,10,12].GC–MS enables precise monitoring of these parent drugs and metabolites in biological samples such as plasma, urine, or tissues[9,13].

From an adverse event perspective, GC-MS is essential to detect and characterize toxic drug metabolites which are responsible for hepatotoxicity, nephrotoxicity, or neurotoxicity. The fragmentation pattern provides a molecular fingerprint that corroborates the presence of deleterious by-products that are produced during drug metabolism. This makes it useful for therapeutic drug monitoring (TDM) and safety monitoring after a drug is approved [12,13].

Principle

The separation and identification principle underlies the operation of gas chromatography–mass spectrometry (GC–MS). Gas chromatography (GC) separates volatile or derivatized drug molecules and their metabolites in the first step by comparing how they interact with the stationary phase of the column and how volatile they are. Mass spectrometry (MS) creates a distinct spectral

fingerprint in the second step by ionizing fragmenting and detecting these separated molecules based on their mass-to-charge ratio (m/z). In the context of adverse events (AEs) and drug-drug interactions (DDIs) this combined principle enables precise identification and measurement of co-administered medications and their metabolites in biological samples assisting in the identification of toxic byproducts or metabolic alteration that cause interactions and negative effects(9,12,13].

Procedure

Here we will also take an example (valproic acid and phenytoin) to get a better understanding of GC–MS

1. Prepare standards & QCs
    - We can make calibration standards by spiking blank plasma with known concentrations of valproic acid (VPA) and phenytoin (PHT) covering expected clinical range.Prepare low/mid/high QCs. Add a fixed amount of internal standard to all tubes[9,12].
2. Aliquot sample
    - Put \~0.5 mL plasma into a clean tube; add IS (fixed volume).
3. Protein removal
    - Add equal volume of acetonitrile (or methanol), vortex 30 s, then centrifuge 10 min. Transfer supernatant.
4. Extraction (clean-up)
    - Perform liquid–liquid extraction with hexane\:ethyl acetate (70:30) (add \~2 mL, vortex, centrifuge). Collect organic layer; repeat once and combine.
5. Evaporate
    - Evaporate the combined organic phase to dryness under nitrogen or in a concentrator.
6. Derivatize (if required for VPA)
    - Add BSTFA + 1% TMCS (or chosen derivatizing reagent) and heat \~60–70 °C for 20–30 min to make analytes volatile for GC[12].
7. Reconstitute & transfer
    - Cool, add \~100 µL GC solvent (e.g., ethyl acetate), transfer to GC vial with insert.
8. GC-MS run (example conditions)
    - Column: DB-5ms (30 m × 0.25 mm). Carrier gas helium, 1.0 mL/min. Injector splitless, 250 °C. Oven ramp from \~80 °C to 300 °C (adjust for your lab). Ionization: EI 70 eV. Acquire in SIM for quantification (monitor characteristic ions) and full-scan for confirmation[9,10].
9. Calibration & quantification
    - Build calibration curve of analyte/IS peak-area ratio vs concentration (use weighted linear regression). Calculate sample concentrations from the curve[12].
10. QC & reporting
    - Ensure QCs meet acceptance (accuracy within ±15%, precision CV ≤15%). Report concentrations and compare PHT levels in monotherapy vs. co-administration with VPA to assess DDI and risk of AE[9,12].



Figure 3: Effect of Valproic Acid on Phenytoin Level.

Advantages of GC–MS

1. High sensitivity and specificity
    - Detects drugs and metabolites at very low concentrations in plasma/urine[9,12].
2. Unique molecular fingerprint
    - Mass spectra provide accurate identification of interacting drugs/metabolites, reducing false positives[11].
3. Separation of complex mixtures
    - GC effectively resolves co-administered drugs before MS detection[9,13].
4. Quantitative and qualitative
    - Simultaneously measures exact concentrations (for PK studies) and identifies unexpected metabolites (linked to AEs)[12;13].
5. Versatile applications
    - Used in therapeutic drug monitoring (TDM), forensic toxicology, post-marketing surveillance[11-13].

Disadvantages of GC–MS

1. Requires volatile/thermally stable compounds
    - Many drugs (e.g., peptides, polar drugs) need chemical derivatization, making workflow longer[12].
2. Sample preparation is complex
    - Extraction and derivatization steps increase time and chance of error[9].
3. Instrument cost and maintenance
    - GC–MS systems are expensive and need skilled operators[10,12].
4. Lower suitability for large biomolecules
    - Not ideal for protein or highly polar drug interactions (LC–MS is better in those cases)[1,2,5].
5. Throughput limitation
    - Longer analysis time compared to newer high-resolution LC–MS/MS methods[17,21].

Future Prospective of GC-MS

1. Enhanced Sensitivity and Selectivity
    - GC-MS is already well-known for having excellent specificity and sensitivity. High-resolution mass spectrometry (HRMS) and tandem GC-MS/MS are two examples of future technological advancements that will make it possible to detect even trace amounts of medications metabolites and their interactions. This will be especially helpful for low-dose or uncommon drug combinations that are otherwise challenging to track in tissues or plasma. [9,13].
2. Integration with Metabolomics for DDI Profiling
    - GC-MS can be coupled with metabolomics approaches to study metabolic changes induced by drug-drug interactions. This integration will help in predicting adverse events and understanding mechanisms of toxicity at a molecular level, improving personalized therapy strategies[9,10].
3. Regulatory and Clinical Implications
    - With the push for personalized medicine, regulatory agencies may encourage the use of GC-MS-based monitoring for high-risk drugs. Its future role could extend to real-time pharmacovigilance, identifying adverse reactions early and minimizing patient risk[19,21].
4. Complementary Use with Other Bioanalytical Techniques
    - GC-MS may increasingly be combined with LC-MS/MS, NMR, and other spectroscopic methods to provide a holistic view of DDIs and AEs, including volatile, non-volatile, and thermally labile drug metabolites. Such hybrid approaches will enhance the accuracy of adverse event detection[12,22].
5. Automation and High-Throughput Screening
    - Future GC-MS platforms are likely to be highly automated, enabling simultaneous analysis of multiple drugs and metabolites. This will reduce human error and turnaround time in pharmacokinetic and toxicological studies, particularly in post-marketing surveillance[9,13].

Figure 4: GC-MS Instrument.



Figure 5: Trends of Analysis Technique for DDIs & AEs Detection in Pharma (2005-2025).

- GC-MS → stable but moderate use, mainly for specific volatile/derivatized drugs.
- LC-MS → strong growth, now the gold standard for DDI/AE monitoring.
- Immunoassay → historically dominant, but gradually declining as LC-MS and biosensors expand.
- Biosensors → rapid rise in recent years, projected to be highly influential for real-time and point-of-care monitoring.

Clinical and Preclinical Applications of DDIs and AE

Bioanalytical tools are extensively applied in both preclinical research and clinical trials to monitor drug interactions and detect potential toxicities. For example: - Methotrexate monitoring by HPLC to avoid toxicity in cancer patients[5,6,15]. Warfarin interactions with antibiotics detected using LC-MS/MS to prevent bleeding events. - Antiretroviral drugs assessed via LC-MS for hepatotoxicity and DDIs. - Rifampicin interactions monitored for effects on cytochrome P450 enzymes. Such applications help in adjusting doses, identifying high-risk populations, and supporting safer therapeutic regimens[19-21].

Regulatory and Pharmacovigilance Perspective

Regulatoryly speaking tracking adverse events (AEs) and drug-drug interactions (DDIs) is crucial to the development and approval

of new drugs. Using validated bioanalytical techniques regulatory bodies like the FDA EMA PMDA and CDSCO require the systematic evaluation of potential DDIs during the preclinical and clinical phases [4,17,18]. The gold standard for measuring drug and metabolite levels in preclinical research is LC-MS/MS. In vitro and in vivo experiments are carried out to evaluate enzyme inhibition or induction especially involving CYP450 isoenzymes [1,2,4]. Bioanalytical assays such as LC-MS/MS and immunoassays are used in clinical trials to measure drug plasma concentrations and validate interaction risks. This is evident in regulatory requirements for CYP3A4 substrates like the midazolam–ketoconazole interaction study [16,18]. Biosensors are showing promise as real-time patient monitoring tools under regulatory review while post-marketing surveillance (Phase IV) also entails regulatory oversight where unexpected DDIs and AEs must be confirmed using techniques like GC-MS and LC-MS/MS [9,12,22].

From a pharmacovigilance (PV) perspective, the focus is on the continuous detection, assessment, and prevention of adverse events after a drug has been marketed. Spontaneous reporting systems such as FDA's FAERS, WHO's VigiBase, and India's PvPI collect AE and DDI signals, which are subsequently confirmed using robust analytical tools[19,21]. Immunoassays remain commonly used in clinical laboratories for rapid detection of toxic drug levels, such as methotrexate monitoring to prevent life-threatening toxicity[17]. whereas LC-MS/MS provides confirmatory evidence in PV case validation[16,18]. GC-MS also plays a role in identifying toxic metabolites, such as NAPQI in paracetamol-induced hepatotoxicity[9,11].

Abbreviation

- AE – Adverse Event
- DDI – Drug–Drug Interaction
- GC-MS – Gas Chromatography-Mass Spectrometry
- LC-MS – Liquid Chromatography-Mass Spectrometry
- HPLC – High-Performance Liquid Chromatography
- TDM – Therapeutic Drug Monitoring
- PV – Pharmacovigilance
- VPA – Vaproic Acid
- PHT – Phenytoin

CONCLUSION

This review emphasizes how important bioanalytical methods are for tracking and describing DDIs and ADRs. These methods include spectroscopy immunoassays gas chromatography–mass spectrometry (GC-MS) liquid chromatography–mass spectrometry (LC-MS/MS) and emerging biosensor technologies. Drugs metabolites and biomarkers in a variety of biological matrices can be precisely quantified thanks to these techniques high sensitivity reproducibility and specificity. Pharmacovigilance is improved and laboratory data is connected with clinical decision-making when bioanalytical approaches are integrated into preclinical research clinical trials and post-marketing surveillance. In order to guarantee patient safety and support risk assessment dose modifications and labeling changes regulatory bodies like the FDA EMA and CDSCO place a high priority on validated bioanalytical methodologies. Additionally these methods are opening the door to a more individualized and predictive medical model by combining with pharmacogenomics biomarker discovery and artificial intelligence.

REFRENCES

1. Matuszewski B K., Constanzer M L., and Chavez-Eng C M; Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC−MS/MS; Anal. Chem; 2003; 75 (13);3019-3030
2. Enke C G; Anal. Chem; f LC-MS Bioanalysis: Best Practices, Experimental Protocols; Anal. Chem; 1997; 69; 4885-4893
3. A.G. Rowley; Evaluating Uncertainty for Laboratories; A Practical Handbook; IJPQA; 2001; 4(3); 1-8
4. Vishwananthan C T., Bansal S., Booth B., Destefano A J., Rose M J., Sailstad J; Workshop/conference reportquantitative bioanalytical methods validation and implementation; best practices for chromatographic and ligand binding assays; AAPS J; 2007; 9(2); 117-121.
5. Sethi P D; HPLC quantitative analysis of pharmaceutical formulation; New Delhi: CBS Publication and Distributors; IJAPA; 3(4); 2001; 8-40.
6. Snyder L R., Kirkland J and J., Glajch J L; Practical HPLC Method Development; Wiley Interscience Publication, John Wiley & Sons; 1997; Issue no:2230-7885; 205-15.
7. Causon R; Application issues in bioanalytical method validation;sample analysis; J. Pharm. Sci; 1979;68; 237– 238
8. Shrinagar naik K., Priyadarsdhi., and Tripathy; Standardization; ISO 9000:2000 Quality management systems—Fundamentals and vocabulary; 2008; 1; 1-10
9. Amirav A., Gordin A., Poliak M., Alon T., and Fialkov A. B; Gas Chromatography Mass Spectrometry with Supersonic Molecular Beams; Journal of Mass Spectrometry; 2008; 43(2); 141–163 1
10. Alon, T., and Amirav A; Isotope Abundance Analysis Method and Software for Improved Sample Identification with the Supersonic GC-M; Rapid Communications in Mass Spectrometry; IJPQA;2006; 20(17); 2579–

2588
11. Robert P., and Dr Adams; Identification of Essential Oil Components By Gas Chromatography/Mass Spectrometry; AJRC; 2008;2(4);380-387
12. Adlard E. R., Handley., and Alan J; Gas chromatographic techniques and applications; Sheffield Academic; IJPQA; 2001; 4(3); 2-16
13. Eugene F., Barry., Grob., and Robert Lee; Modern practice of gas chromatography.New York; WileyInterscience; IJPQA; 2004.4(3)1-10
14. Eiceman G.A; Gas Chromatography. In R.A. Meyers (Ed.); Encyclopedia of Analytical Chemistry: Applications, Theory, and Instrumentation,; Chichester: Wiley. ISBN 0-471-97670-9; 2000;1;10627

15. Kazakevich Y., and Lobrutto R; HPLC for Pharmaceutical Scientists; John Wiley & Sons, Inc: New Jersey; JPBMS; 2007; 1; 281-292
16. Said R; Application of New Technology LC-MS/MS for determination of therapeutic drugs, Doctoral degree thesis, Department of Medicine Division of Clinical Pharmacology Karolinska Institute, Stockholm, Sweden;IJCPCR; 2010;1;1-5
17. Thurman EM., and Mils MS; Solid Phase extraction: Principles and Practice. Chemical Analysis: A series of monographs on analytical chemistry and its applications; IJCPCR;2;1998; 147
18. Venn RF; a review on bioanalytical method development and. Validation by using lc-ms/ms; Principles and Practice of Bioanalysis;IJCPCR;2000;18;364
19. Shah VP; The History of Bioanalytical Method Validation and Regulation: Evolution of a Guidance Document on Bioanalytical Method Validation; AAPS J ; 2007; 9; E43-E47
20. Buick AR., Doig MV., Jeal SC., Land GS., and Mc Dowall RD; Method Validation in the Bioanalytical laboratory; J.Pharm BioMed Anal ; 1990; 8: 629-637.
21. Causon R; Validation of chromatographic methods in Bioanalytical analysis: View point and Discussion; J Chromatogr B Biomed Sci Appl ; 1997; 689; 175-180.
22. Rozet E., Marini RD., Ziemons E., Boulanger B., and Hubbert P; Advances in Validation, Risk and Uncertainty assessment; Bioanalytical method validation; J Pharm Biomed Anal; 2011; 55; 848-858.
23. evosciences.com/en/spectrometrie-de-masse/33-waters-xevo-tqs hclass.html
24. azom.com/equipment-details.aspx?EquipID=902
25. shimadzu.com/an/industry/foodbeverages/qn50420000001ua7-img/qn50420000002ffj.jpg
26. science.sjp.ac.lk/wp-content/uploads/2012/06/GC-MS_instrument_flatform.jpg
27. chem.agilent.com/en-US/products-services/Instruments-Systems/Automated-Electrophoresis/CE-MS-